Crisnatol (BWA770U) is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts .
In Vitro
Crisnatol (1.3 μg/mL; 24-72 h) inhibits the replication of HepG2 cells, decreases cell viability by 35%. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HepG2 cells Concentration: 1.3 μg/mL Incubation Time: 24 hours, 48 hours, 72 hours, and 126 hours Result: Inhibited cell viability at 48 hr.
In Vivo
Crisnatol (25 mg/kg; p.o.; single dose) shows oral activity and shows stable metabolite profile extract of rat feces by autoradiography. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
Specifications
Specifications & Purity
≥99%
Biochemical and Physiological Mechanisms
Crisnatol (BWA770U) is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts
Storage
Store at 2-8°C,Protected from light,Desiccated
Shipped In
Wet ice
This product requires cold chain shipping. Ground and other economy services are not available.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
